In Vivo2022 turned out to be a relatively quiet year on the M&A and partnering front in Japan – or at least it was until mid-December, when Takeda Pharmaceutical Co. Ltd. announced it would pay an eye-wate
Scrip2022 turned out to be a relatively quiet year on the M&A and partnering front in Japan – or at least it was until mid-December, when Takeda Pharmaceutical Co. Ltd. announced it would pay an eye-wate
In VivoRoche Holding AG , Genentech, Inc. and their affiliated companies were the busiest deal makers in the biopharmaceutical sector for the second consecutive year in 2021, with 23 deals across all cate
ScripTakeda Pharmaceutical Co. Ltd. has upgraded revenue and profit projections for its full fiscal year on the back of what it said was “robust topline growth” for its portfolio of 14 global brands, led